CMB International: Raising the target price of China Biopharmaceuticals (01177) to HK$9 to maintain a “buy” rating

Zhitongcaijing · 2d ago

The Zhitong Finance App learned that CMB International released a research report saying that China Biopharmaceutical (01177) has recently continued to make breakthroughs in both commercialization and internationalization of innovative drugs. Considering the company's continued execution of BD transactions in 2026, the bank raised its forecast. From 2026 to 2028, revenue is expected to increase by 11.5%, 13.2% and 10.4%, respectively, and adjusted net profit to mother will increase by 12.5%, 19.4%, and 9.9%, respectively. The bank maintained a “buy” rating, and the target price was raised from HK$8.7 to HK$9.

On November 14, 2026, the National Health Insurance Administration announced the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2026)”. The company's core enterprise, Zhengda Tianqing, included 3 innovative drugs in the catalogue for the first time, 2 innovative drugs with new indications, and successfully renewed 2 innovative drugs.

According to the report, the company also recently reached a platform-based BD cooperation with multinational pharmaceutical company Boehringer Ingelheim (BI), involving a down payment of US$358 million and recent payments, a total potential amount of about US$7 billion, and a double-digit sales share, continuing the strong trend of the company's foreign cooperation in 2026.

The bank believes that the expansion of medical insurance is expected to accelerate the commercial transformation of innovative biopharmaceutical products in China, while cooperation with BI will verify the value of the company's early research platform and consolidate the foundation for long-term growth of the innovative business.